[Sapylin immunotherapy in oral squamous cancer].
A streptococcal preparation, Sapylin, was employed for 27 cases of oral squamous cancer without treatment that was injected into normal submucosa or sub-skin around the tumor. The recent clinical efficacy is as follows: 3 cases specially effective, 10 cases marked effective, 6 cases effective and 8 cases not effective. Effective percent 70%. A delayed SK-SD skin reaction were found to enhance, but NK activity and T-Rosette were not. A middle grade fever was present as a side effect of this preparation. The result suggested Sapylin that may be a useful to biological response modifier (BRM) agent for oral squamous cancer.
Lu
C Y
CY
School of Stomatology, Shanghai Second Medical University.
D001688:Biological Products / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016233:Immunotherapy, Active; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*
D001688:Biological Products; D007155:Immunologic Factors; C569879:streptococcal preparation 722; D010844:Picibanil